Tissue Regenix Group Plc (TRX.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | -930 | 1,073 | -702 | -512 | -15 |
| Other Working Capital | -3,588 | -239 | -616 | -468 | -4,012 |
| Other Operating Activity | 2,883 | 206 | 24 | -1,995 | -3,099 |
| Operating Cash Flow | $-1,635 | $1,040 | $-1,294 | $-2,975 | $-7,126 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,299 | -413 | -381 | -1,550 | -1,578 |
| Other Investing Activity | -759 | -424 | -701 | -494 | -290 |
| Investing Cash Flow | $-4,058 | $-837 | $-1,082 | $-2,044 | $-1,868 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 4,273 | N/A | 1,708 | 602 | 687 |
| Debt Repayment | -20 | N/A | N/A | N/A | 0 |
| Common Stock Issued | 104 | 74 | 9 | N/A | 19,968 |
| Other Financing Activity | -1,078 | -1,586 | -807 | -794 | -1,888 |
| Financing Cash Flow | $3,279 | $-1,512 | $910 | $-192 | $18,767 |
| Exchange Rate Effect | -21 | 10 | -294 | -48 | -1 |
| Beginning Cash Position | 4,650 | 5,949 | 7,709 | 12,968 | 3,244 |
| End Cash Position | 2,215 | 4,650 | 5,949 | 7,709 | 13,015 |
| Net Cash Flow | $-2,414 | $-1,309 | $-1,466 | $-5,211 | $9,773 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,635 | 1,040 | -1,294 | -2,975 | -7,126 |
| Capital Expenditure | -4,069 | -863 | -1,090 | -2,047 | -1,871 |
| Free Cash Flow | -5,704 | 177 | -2,384 | -5,022 | -8,997 |